Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

IMCI and ETAT integration at a primary healthcare facility in Malawi: a human factors approach.

Robertson SK, Manson K, Fioratou E.

BMC Health Serv Res. 2018 Dec 29;18(1):1014. doi: 10.1186/s12913-018-3803-5.

2.

Effects of chronic cannabinoid exposure during adolescence on reward preference and mPFC activation in adulthood.

Jacobs-Brichford E, Manson KF, Roitman JD.

Physiol Behav. 2019 Feb 1;199:395-404. doi: 10.1016/j.physbeh.2018.12.006. Epub 2018 Dec 5.

PMID:
30529340
3.

Do community pharmacist performance evaluations capture the modern pharmacist's role? Mapping competencies assessed in Canadian community pharmacy performance evaluation templates against the General Level Framework.

Chong IYM, Rosenthal MM, Manson KR, Houle SKD.

J Am Pharm Assoc (2003). 2018 Nov - Dec;58(6):638-642.e2. doi: 10.1016/j.japh.2018.08.006. Epub 2018 Sep 17.

PMID:
30237009
4.

Dissociating Value Representation and Inhibition of Inappropriate Affective Response during Reversal Learning in the Ventromedial Prefrontal Cortex.

Zhang Z, Mendelsohn A, Manson KF, Schiller D, Levy I.

eNeuro. 2016 Jan 4;2(6). pii: ENEURO.0072-15.2015. doi: 10.1523/ENEURO.0072-15.2015. eCollection 2015 Nov-Dec.

5.

"Selling" value: the influence of language on willingness-to-accept.

Manson KF, Levy I.

PLoS One. 2015 Mar 30;10(3):e0120292. doi: 10.1371/journal.pone.0120292. eCollection 2015.

6.

Impaired associative learning with food rewards in obese women.

Zhang Z, Manson KF, Schiller D, Levy I.

Curr Biol. 2014 Aug 4;24(15):1731-6. doi: 10.1016/j.cub.2014.05.075. Epub 2014 Jul 17.

7.

Adolescents' risk-taking behavior is driven by tolerance to ambiguity.

Tymula A, Rosenberg Belmaker LA, Roy AK, Ruderman L, Manson K, Glimcher PW, Levy I.

Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):17135-40. doi: 10.1073/pnas.1207144109. Epub 2012 Oct 1.

8.

Measuring the subjective value of risky and ambiguous options using experimental economics and functional MRI methods.

Levy I, Rosenberg Belmaker L, Manson K, Tymula A, Glimcher PW.

J Vis Exp. 2012 Sep 19;(67):e3724. doi: 10.3791/3724.

9.

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.

J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.

10.

Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer.

Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo KS, Kim DW, Marshall J.

J Transl Med. 2007 Nov 26;5:60.

11.

Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors.

Santra S, Sun Y, Parvani JG, Philippon V, Wyand MS, Manson K, Gomez-Yafal A, Mazzara G, Panicali D, Markham PD, Montefiori DC, Letvin NL.

J Virol. 2007 Aug;81(16):8563-70. Epub 2007 Jun 6.

12.

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.

DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T.

J Transl Med. 2006 Jan 3;4:1.

13.

Self-discrepancies in bipolar disorder: comparison of manic, depressed, remitted and normal participants.

Bentall RP, Kinderman P, Manson K.

Br J Clin Psychol. 2005 Nov;44(Pt 4):457-73.

PMID:
16368026
14.

Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques.

Schmitz JE, Johnson RP, McClure HM, Manson KH, Wyand MS, Kuroda MJ, Lifton MA, Khunkhun RS, McEvers KJ, Gillis J, Piatak M, Lifson JD, Grosschupff G, Racz P, Tenner-Racz K, Rieber EP, Kuus-Reichel K, Gelman RS, Letvin NL, Montefiori DC, Ruprecht RM, Desrosiers RC, Reimann KA.

J Virol. 2005 Jul;79(13):8131-41.

15.

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.

Kaufman HL, Deraffele G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, Cheung K, Lee DS, Divito J, Voulo M, Donovan J, Dolan K, Manson K, Panicali D, Wang E, Hörig H, Marincola FM.

J Clin Invest. 2005 Jul;115(7):1903-12. Epub 2005 Jun 2.

16.

Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.

Jackson SS, Ilyinskii P, Philippon V, Gritz L, Yafal AG, Zinnack K, Beaudry KR, Manson KH, Lifton MA, Kuroda MJ, Letvin NL, Mazzara GP, Panicali DL.

J Virol. 2005 May;79(10):6554-9.

17.

Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes.

Sun Y, Schmitz JE, Acierno PM, Santra S, Subbramanian RA, Barouch DH, Gorgone DA, Lifton MA, Beaudry KR, Manson K, Philippon V, Xu L, Maecker HT, Mascola JR, Panicali D, Nabel GJ, Letvin NL.

J Immunol. 2005 Apr 15;174(8):4753-60.

18.

Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys.

Seaman MS, Santra S, Newberg MH, Philippon V, Manson K, Xu L, Gelman RS, Panicali D, Mascola JR, Nabel GJ, Letvin NL.

J Virol. 2005 Apr;79(8):4580-8.

19.

Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.

Tsang KY, Palena C, Yokokawa J, Arlen PM, Gulley JL, Mazzara GP, Gritz L, Yafal AG, Ogueta S, Greenhalgh P, Manson K, Panicali D, Schlom J.

Clin Cancer Res. 2005 Feb 15;11(4):1597-607.

20.

Kinetics of expansion of SIV Gag-specific CD8+ T lymphocytes following challenge of vaccinated macaques.

Abdel-Motal UM, Gillis J, Manson K, Wyand M, Montefiori D, Stefano-Cole K, Montelaro RC, Altman JD, Johnson RP.

Virology. 2005 Mar 15;333(2):226-38.

21.

Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.

Silvera P, Savary JR, Livingston V, White J, Manson KH, Wyand MH, Salk PL, Moss RB, Lewis MG.

Vaccine. 2004 Dec 21;23(6):827-39.

PMID:
15542208
22.

An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.

Wang SW, Bertley FM, Kozlowski PA, Herrmann L, Manson K, Mazzara G, Piatak M, Johnson RP, Carville A, Mansfield K, Aldovini A.

AIDS Res Hum Retroviruses. 2004 Aug;20(8):846-59.

PMID:
15320989
23.

Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses.

Santra S, Barouch DH, Korioth-Schmitz B, Lord CI, Krivulka GR, Yu F, Beddall MH, Gorgone DA, Lifton MA, Miura A, Philippon V, Manson K, Markham PD, Parrish J, Kuroda MJ, Schmitz JE, Gelman RS, Shiver JW, Montefiori DC, Panicali D, Letvin NL.

Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11088-93. Epub 2004 Jul 16.

24.

A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques.

Muthumani K, Bagarazzi M, Conway D, Hwang DS, Manson K, Ciccarelli R, Israel Z, Montefiori DC, Ugen K, Miller N, Kim J, Boyer J, Weiner DB.

Vaccine. 2003 Jan 30;21(7-8):629-37.

PMID:
12531331
25.

Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine.

Voss G, Manson K, Montefiori D, Watkins DI, Heeney J, Wyand M, Cohen J, Bruck C.

J Virol. 2003 Jan;77(2):1049-58.

26.

Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques.

Muthumani K, Bagarazzi M, Conway D, Hwang DS, Ayyavoo V, Zhang D, Manson K, Kim J, Boyer J, Weiner DB.

J Med Primatol. 2002 Aug;31(4-5):179-85.

PMID:
12390540
27.

IL-4 increases Simian immunodeficiency virus replication despite enhanced SIV immune responses in infected rhesus macaques.

Boyer JD, Nath B, Schumann K, Curley E, Manson K, Kim J, Weiner DB.

Int J Parasitol. 2002 May;32(5):543-50.

PMID:
11943227
28.

Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen.

Kim JJ, Yang JS, Nottingham LK, Tang W, Dang K, Manson KH, Wyand MS, Wilson DM, Weiner DB.

Oncogene. 2001 Jul 27;20(33):4497-506.

29.

Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization.

Kim JJ, Yang JS, Nottingham LK, Lee DJ, Lee M, Manson KH, Wyand MS, Boyer JD, Ugen KE, Weiner DB.

Virology. 2001 Jul 5;285(2):204-17.

30.
31.

The use of hydrogen peroxide to enhance the efficacy of doxorubicin hydrochloride in a murine bladder tumor cell line.

Loughlin KR, Manson K, Cragnale D, Wilson L, Ball RA, Bridges KR.

J Urol. 2001 Apr;165(4):1300-4.

PMID:
11257705
32.
33.
34.

Evaluation of cytotoxic T-lymphocyte responses in human and nonhuman primate subjects infected with human immunodeficiency virus type 1 or simian/human immunodeficiency virus.

Fu TM, Freed DC, Trigona WL, Guan L, Zhu L, Long R, Persaud NV, Manson K, Dubey S, Shiver JW.

J Virol. 2001 Jan;75(1):73-82.

35.

Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions.

Wang SW, Kozlowski PA, Schmelz G, Manson K, Wyand MS, Glickman R, Montefiori D, Lifson JD, Johnson RP, Neutra MR, Aldovini A.

J Virol. 2000 Nov;74(22):10514-22.

36.

Effect of a cellulose acetate phthalate topical cream on vaginal transmission of simian immunodeficiency virus in rhesus monkeys.

Manson KH, Wyand MS, Miller C, Neurath AR.

Antimicrob Agents Chemother. 2000 Nov;44(11):3199-202.

37.

Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.

Egan MA, Charini WA, Kuroda MJ, Schmitz JE, Racz P, Tenner-Racz K, Manson K, Wyand M, Lifton MA, Nickerson CE, Fu T, Shiver JW, Letvin NL.

J Virol. 2000 Aug;74(16):7485-95.

39.

Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants.

Kim JJ, Yang JS, VanCott TC, Lee DJ, Manson KH, Wyand MS, Boyer JD, Ugen KE, Weiner DB.

J Virol. 2000 Apr;74(7):3427-9.

40.

Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants.

Kim JJ, Nottingham LK, Tsai A, Lee DJ, Maguire HC, Oh J, Dentchev T, Manson KH, Wyand MS, Agadjanyan MG, Ugen KE, Weiner DB.

J Med Primatol. 1999 Aug-Oct;28(4-5):214-23.

PMID:
10593488
41.

Characterization of primary isolate-like variants of simian-human immunodeficiency virus.

Crawford JM, Earl PL, Moss B, Reimann KA, Wyand MS, Manson KH, Bilska M, Zhou JT, Pauza CD, Parren PW, Burton DR, Sodroski JG, Letvin NL, Montefiori DC.

J Virol. 1999 Dec;73(12):10199-207.

42.

Protection by live, attenuated simian immunodeficiency virus against heterologous challenge.

Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, Desrosiers RC.

J Virol. 1999 Oct;73(10):8356-63.

43.

Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation.

Johnson RP, Lifson JD, Czajak SC, Cole KS, Manson KH, Glickman R, Yang J, Montefiori DC, Montelaro R, Wyand MS, Desrosiers RC.

J Virol. 1999 Jun;73(6):4952-61.

44.

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations.

Robinson HL, Montefiori DC, Johnson RP, Manson KH, Kalish ML, Lifson JD, Rizvi TA, Lu S, Hu SL, Mazzara GP, Panicali DL, Herndon JG, Glickman R, Candido MA, Lydy SL, Wyand MS, McClure HM.

Nat Med. 1999 May;5(5):526-34.

PMID:
10229229
45.

Effect of 3-hydroxyphthaloyl-beta-lactoglobulin on vaginal transmission of simian immunodeficiency virus in rhesus monkeys.

Wyand MS, Manson KH, Miller CJ, Neurath AR.

Antimicrob Agents Chemother. 1999 Apr;43(4):978-80.

46.

Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus.

Langlois AJ, Desrosiers RC, Lewis MG, KewalRamani VN, Littman DR, Zhou JY, Manson K, Wyand MS, Bolognesi DP, Montefiori DC.

J Virol. 1998 Aug;72(8):6950-5.

48.

SIV DNA vaccine trial in macaques: post-challenge necropsy in vaccine and control groups.

Lu S, Manson K, Wyand M, Robinson HL.

Vaccine. 1997 Jun;15(8):920-3.

PMID:
9234548
49.

Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus.

Wyand MS, Manson KH, Lackner AA, Desrosiers RC.

Nat Med. 1997 Jan;3(1):32-6.

PMID:
8986737
50.

Utility of SHIV for testing HIV-1 vaccine candidates in macaques.

Lu Y, Salvato MS, Pauza CD, Li J, Sodroski J, Manson K, Wyand M, Letvin N, Jenkins S, Touzjian N, Chutkowski C, Kushner N, LeFaile M, Payne LG, Roberts B.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):99-106.

PMID:
8680896

Supplemental Content

Loading ...
Support Center